Shopping Cart 0
Cart Subtotal
AED 0

Metabolic Disorders Drugs MGR 2017

Bundle Purchase

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 14680

Access to Printed Report; No Soft Copy
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : Printed Publication/ Book by Post

Hard Copy License
AED 14680

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 22020

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

CD-Rom
AED 14680

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 29360

Details

Metabolic disorders drugs market covers medications that are used in the treatment of diseases such as diabetes, thyroid, hyperparathyroidism, hypopituitarism, hypoadrenalism and other metabolic diseases. Some of the major drugs used in the treatment metabolic diseases are Lantus (type 1 and 2 diabetes), Januvia (diabetes), and other drugs.

The global metabolic disorders drugs market was estimated to be around $80 billion as of 2016. The metabolic disorders drugs market made up around 7% of the overall pharmaceuticals market in 2016. The metabolic disorders drugs market was the seventh largest market in the global pharmaceutical market in 2016.

Acquisitions

Strategic acquisitions of small companies by market leaders in the market to strengthen their market position is one of the major trend in the market. For instance, in August 2015 Novo Nordisk acquired Calibrium LLC and MB2 LLC, a US based biopharmaceutical research companies. Through the acquisitions Novo Nordisk focuses on expanding its obesity and diabetes product line by integrating Calibrium LLC and MB2 LLC companies.

The Metabolic Disorders Drugs Market Global Report provides strategists, marketers and senior management with the critical information they need to assess the global metabolic disorders drugs sector.

Reasons to Purchase

Outperform competitors using accurate up to date demand-side dynamics information.

Identify growth segments for investment.

Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.

Create regional and country strategies on the basis of local data and analysis.

Stay abreast of the latest customer and market research findings

Benchmark performance against key competitors.

Develop strategies based on likely future developments.

Utilize the relationships between key data sets for superior strategizing.

Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Gain a global perspective on the development of the market.

Report will be updated with the latest data and delivered to you within 3-5 working days of order.

Description:

Where is the largest and fastest growing market for the metabolic disorders drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The metabolic disorders drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider pharmaceutical drugs market, and compares it with other markets.

The market characteristics section of the report defines and explains the market.

The market size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.

Market segmentations break down market into sub markets.

The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.

Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.

The trends and strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.

The metabolic disorders drugs market section of the report gives context. It compares the metabolic disorders drugs market with other segments of the pharmaceutical drugs market by size and growth, historic and forecast. It analyses Expenditure Per Capita, The Metabolic Disorders Drugs Indicators Comparison.

The industry metrics section looks at critical drivers including patient numbers (epidemiology) hospital beds and specialist physicians while the macro-economic section looks at the market in relation to the overall economy.

Scope

Markets Covered: Anti-Diabetics, Anti-Thyroid Drugs, Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)

Companies Mentioned: Novo Nordisk, Sanofi, Merck & Co., Eli Lilly, and AstraZeneca PLC

Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.

Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa

Time series: Five years historic and forecast.

Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, The Metabolic Disorders Drugs Indicators Comparison.

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

READ MORE

Table Of Content

Scope

1. Metabolic Disorders Drugs Market Characteristics;

2. Metabolic Disorders Drugs Market Size And Growth;

2.1. Historic Market Growth; 2.1.1. Drivers Of The Market; 2.1.2. Restraints On The Market; 2.2. Forecast Market Growth; 2.2.1. Drivers Of The Market; 2.2.2. Restraints On The Market;

3. Pestle Analysis;

3.1. Political; 3.2. Economic; 3.3. Social; 3.4. Technological; 3.5. Legal; 3.6. Environmental;

4. Metabolic Disorders Drugs Market Customer Information;

5. Metabolic Disorders Drugs Market Segmentation;

5.1. Global Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 5.2. Global Metabolic Disorders Drugs Market, 2012-2020, Historic And Forecast, By Segment; 5.3 Global Metabolic Disorders Drugs Market Trends And Strategies;

6. Metabolic Disorders Drugs Market Regional And Country Analysis;

6.1. Global Metabolic Disorders Drugs Market, 2016, By Region; 6.2. Global Metabolic Disorders Drugs Market, 2012-2020, Historic And Forecast, By Region; 6.3. Metabolic Disorders Drugs Market, 2016, By Country; 6.4. Metabolic Disorders Drugs Market, 2012-2020, Historic And Forecast, By Country; 6.5. Global Pharmaceutical Market Segments, 2016, By Region; 6.6. Global Pharmaceutical Drugs Market Segments, 2016, By Region; 6.7. Global Pharmaceutical Market Segments, 2016, By Country; 6.8.Global Pharmaceutical Drugs Market Segments, 2016, By Country;

7. Global Metabolic Disorders Drugs Market Comparison With Macro Economic Factors;

7.1. Metabolic Disorders Drugs Market Size, Percentage Of GDP, Global; 7.2. Per Capita Average Metabolic Disorders Drugs Expenditure, Global;

8. Metabolic Disorders Drugs Market Comparison With Macro Economic Factors Across Countries;

8.1. Metabolic Disorders Drugs Market Size, Percentage Of GDP, By Country; 8.2. Per Capita Average Metabolic Disorders Drugs Expenditure, By Country;

9. Metabolic Disorders Drugs Market Comparison With Industry Metrics;

9.1. Global Number Of Pharmacists, 2016, By Country; 9.2. Global Metabolic Disorders Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country; 9.3. Global Number Of Pharma Enterprises, 2016, By Country; 9.4. Global Metabolic Disorders Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country; 9.5. Global Average Spending On R&D/Product Development, 2016, By Country; 9.6. Global Metabolic Disorders Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country; 9.7. Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.8. Global Metabolic Disorders Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.9. Prevalent Cases Of Hypertension, 2014, By Country; 9.10. Prevalent Cases Of Diabetes, 2015, By Country; 9.11. Global Number Of General Practitioners 2016, By Country; 9.12. Global Metabolic Disorders Drugs Market Revenue Versus Number Of General Practitioners, 2016, By Country;

10. Asia-Pacific Metabolic Disorders Drugs Market;

10.1.1. Asia-Pacific Metabolic Disorders Drugs Market Overview; 10.1.2. Asia-Pacific Metabolic Disorders Drugs Historic Market, 2012-2016; 10.1.3. Asia-Pacific Metabolic Disorders Drugs Forecast Market, 2016-2020; 10.1.4. Asia-Pacific Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 10.2. Asia-Pacific Metabolic Disorders Drugs Market: Country Analysis; 10.3. China Metabolic Disorders Drugs Market; 10.3.1. China Metabolic Disorders Drugs Market Overview; 10.3.2. China Metabolic Disorders Drugs Historic Market, 2012-2016; 10.3.3. China Metabolic D4isorders Forecast Market, 2016-2020; 10.3.4. China Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 10.3.5. China Metabolic Disorders Drugs Percentage Of GDP, 2012-2020; 10.3.6. China Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020; 10.4. India Metabolic Disorders Drugs Market; 10.4.1. India Metabolic Disorders Drugs Market Overview; 10.4.2. India Metabolic Disorders Drugs Historic Market, 2012-2016; 10.4.3. India Metabolic Disorders Drugs Forecast Market, 2016-2020; 10.4.4. India Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 10.4.5. India Metabolic Disorders Drugs Percentage Of GDP, 2012-2020; 10.4.6. India Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020; 10.5. Japan Metabolic Disorders Drugs Market; 10.5.1. Japan Metabolic Disorders Drugs Market Overview; 10.5.2. Japan Metabolic Disorders Drugs Historic Market, 2012-2016; 10.5.3. Japan Metabolic Disorders Drugs Forecast Market, 2016-2020; 10.5.4. Japan Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 10.5.5. Japan Metabolic Disorders Drugs Percentage Of GDP, 2012-2020; 10.5.6. Japan Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020; 10.6. Australia Metabolic Disorders Drugs Market; 10.6.1. Australia Metabolic Disorders Drugs Historic Market, 2012-2016; 10.6.2. Australia Metabolic Disorders Drugs Forecast Market, 2016-2020; 10.6.3. Australia Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 10.6.4. Australia Metabolic Disorders Drugs Percentage Of GDP, 2012-2020; 10.6.5. Australia Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020;

11. Western Europe Metabolic Disorders Drugs Market;

11.1.1. Western Europe Metabolic Disorders Drugs Market Overview; 11.1.2. Western Europe Metabolic Disorders Drugs Historic Market, 2012-2016; 11.1.3. Western Europe Metabolic Disorders Drugs Forecast Market, 2016-2020; 11.1.4. Western Europe Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 11.2. Western Europe Metabolic Disorders Drugs Market: Country Analysis; 11.3. UK Metabolic Disorders Drugs Market; 11.3.1. UK Metabolic Disorders Drugs Market Overview; 11.3.2. UK Metabolic Disorders Drugs Historic Market, 2012-2016; 11.3.3. UK Metabolic Disorders Drugs Forecast Market, 2016-2020; 11.3.4. UK Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 11.3.5. UK Metabolic Disorders Drugs Percentage Of GDP, 2012-2020; 11.3.6. UK Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020; 11.4. Germany Metabolic Disorders Drugs Market; 11.4.1. Germany Metabolic Disorders Drugs Historic Market, 2012-2016; 11.4.2. Germany Metabolic Disorders Drugs Forecast Market, 2016-2020; 11.4.3. Germany Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 11.4.4 Germany Metabolic Disorders Drugs Percentage Of GDP, 2012-2020; 11.4.5 Germany Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020; 11.5 France Metabolic Disorders Drugs Market; 11.5.1 France Metabolic Disorders Drugs Historic Market, 2012-2016; 11.5.2 France Metabolic Disorders Drugs Forecast Market, 2016-2020; 11.5.3 France Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 11.5.4 France Metabolic Disorders Drugs Percentage Of GDP, 2012-2020; 11.5.5 France Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020; 11.6. Italy Metabolic Disorders Drugs Market; 11.6.1. Italy Metabolic Disorders Drugs Historic Market, 2012-2016; 11.6.2. Italy Metabolic Disorders Drugs Forecast Market, 2016-2020; 11.6.3. Italy Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 11.6.4. Italy Metabolic Disorders Drugs Percentage Of GDP, 2012-2020; 11.6.5. Italy Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020; 11.7. Spain Metabolic Disorders Drugs Market; 11.7.1. Spain Metabolic Disorders Drugs Historic Market, 2012-2016; 11.7.2. Spain Metabolic Disorders Drugs Forecast Market, 2016-2020; 11.7.3. Spain Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 11.7.4. Spain Metabolic Disorders Drugs Percentage Of GDP, 2012-2020; 11.7.5. Spain Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020;

12. Eastern Europe Metabolic Disorders Drugs Market;

12.1.1. Eastern Europe Metabolic Disorders Drugs Market Overview; 12.1.2. Eastern Europe Metabolic Disorders Drugs Historic Market, 2012-2016; 12.1.3. Eastern Europe Metabolic Disorders Drugs Forecast Market, 2016-2020; 12.1.4 Eastern Europe Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 12.2. Eastern Europe Metabolic Disorders Drugs Market: Country Analysis; 12.3. Russia Metabolic Disorders Drugs Market; 12.3.1. Russia Metabolic Disorders Drugs Historic Market, 2012-2016; 12.3.2. Russia Metabolic Disorders Drugs Forecast Market, 2016-2020; 12.3.3. Russia Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 12.3.4. Russia Metabolic Disorders Drugs Percentage Of GDP, 2012-2020; 12.3.5. Russia Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020;

13. North America Metabolic Disorders Drugs Market;

13.1.1. North America Metabolic Disorders Drugs Market Overview; 13.1.2. North America Metabolic Disorders Drugs Historic Market, 2012-2016; 13.1.3. North America Metabolic Disorders Drugs Forecast Market, 2016-2020; 13.1.4. North America Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 13.2. North America Metabolic Disorders Drugs Market: Country Analysis; 13.3. USA Metabolic Disorders Drugs Market; 13.3.1. USA Metabolic Disorders Drugs Historic Market, 2012-2016; 13.3.2. USA Metabolic Disorders Drugs Forecast Market, 2016-2020; 13.3.3 USA Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 13.3.4. USA Metabolic Disorders Drugs Percentage Of GDP, 2012-2020; 13.3.5. USA Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020;

14. South America Metabolic Disorders Drugs Market;

14.1.1. South America Metabolic Disorders Drugs Market Overview; 14.1.2. South America Metabolic Disorders Drugs Historic Market, 2012-2016; 14.1.3. South America Metabolic Disorders Drugs Forecast Market, 2016-2020; 14.1.4. South America Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 14.2. South America Metabolic Disorders Drugs Market: Country Analysis; 14.3. Brazil Metabolic Disorders Drugs Market; 14.3.1. Brazil Metabolic Disorders Drugs Historic Market, 2012-2016; 14.3.2. Brazil Metabolic Disorders Drugs Forecast Market, 2016-2020; 14.3.3. Brazil Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 14.3.4. Brazil Metabolic Disorders Drugs Percentage Of GDP, 2012-2020; 14.3.5. Brazil Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020;

15. Middle East Metabolic Disorders Drugs Market;

15.1.1. Middle East Metabolic Disorders Drugs Market Overview; 15.1.2. Middle East Metabolic Disorders Drugs Historic Market, 2012-2016; 15.1.3. Middle East Metabolic Disorders Drugs Forecast Market, 2016-2020; 15.1.4. Middle East Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism);

16. Africa Metabolic Disorders Drugs Market;

16.1.1. Africa Metabolic Disorders Drugs Market Overview; 16.1.2. Africa Metabolic Disorders Drugs Historic Market, 2012-2016; 16.1.3. Africa Metabolic Disorders Drugs Forecast Market, 2016-2020; 16.1.4. Africa Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism);

17. Metabolic Disorders Drugs Market Competitive Landscape;

17.1. Company Profiles; 17.2. Novo Nordisk; 17.2.1. Overview; 17.2.2. Products And Services; 17.2.3. Strategy; 17.2.4. Financial Performance; 17.3. Sanofi; 17.3.1. Overview; 17.3.2. Products And Services; 17.3.3. Strategy; 17.3.4. Financial Performance; 17.4. Merck & Co.; 17.4.1. Overview; 17.4.2. Products And Services; 17.4.3. Strategy; 17.4.4. Financial Performance; 17.5. Eli Lilly; 17.5.1. Overview; 17.5.2. Products And Services; 17.5.3. Strategy; 17.5.4. Financial Performance; 17.6. Astrazeneca PLC; 17.6.1. Overview; 17.6.2. Products And Services; 17.6.3. Strategy; 17.6.4. Financial Performance;

18. Key Mergers And Acquisitions In The Metabolic Disorders Drugs Market;

19. Market Background: Pharmaceutical Drugs Market;

19.1.1. Pharmaceutical Drugs Market Characteristics; 19.1.2. Pharmaceutical Drugs Market Historic Growth; 19.1.2.1. Drivers Of The Market; 19.1.2.2. Restraints Of The Market; 19.1.3. Pharmaceutical Drugs Market Forecast Growth; 19.1.3.1. Drivers Of The Market; 19.1.3.2. Restraints Of The Market; 19.1.4. Pharmaceutical Drugs Trends And Strategies; 19.2. Pharmaceutical Drugs Market Regional And Country Analysis; 19.2.1. Global Pharmaceutical Drugs Market, 2016, By Region; 19.2.2. Global Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Region; 19.2.3. Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Country; 19.2.4. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment; 19.2.5. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment; 19.3. Global Pharmaceutical Drugs Market Comparison With Macro Economic Factors; 19.3.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, Global; 19.3.2. Per Capita Average Pharmaceutical Drugs Expenditure, Global; 19.4. Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries; 19.4.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country; 19.4.2. Per Capita Average Pharmaceutical Drugs Expenditure, By Country; 19.5. Key Mergers And Acquisitions In The Pharmaceutical Drugs Market;

20. Pharmaceuticals Industry Financial Margins;

21. Appendix;

21.1. NAICS Definitions Of Industry Covered In This Report; 21.2. Abbreviations; 21.3. Currencies; 21.4. Research Inquiries; 21.5. The Business Research Company; 21.6. Copyright And Disclaimer


List Of Figure

Table 1: Global Metabolic Disorders Drugs Historic Market Growth

Table 2: Global Metabolic Disorders Drugs Forecast Market Growth

Table 3: Metabolic Disorders Drugs Market Segmentation

Table 4: Global Metabolic Disorders Drugs Market, 2016, By Segment

Table 5: Global Metabolic Disorders Drugs Market, 2012-2020, Historic And Forecast, By Segment

Table 6: Global Metabolic Disorders Drugs Market, 2016, By Region

Table 7: Global Metabolic Disorders Drugs Market, 2012-2020, Historic And Forecast, By Region

Table 8: Metabolic Disorders Drugs Market, 2016, By Country

Table 9: Metabolic Disorders Drugs Market, 2012-2020, Historic And Forecast, By Country

Table 10: Global Pharmaceutical Market Segments, 2016, By Region

Table 11: Global Pharmaceutical Drugs Market Segments, 2016, By Region

Table 12: Global Pharmaceutical Market Segments, 2016, By Country

Table 13: Global Pharmaceutical Drugs Market Segments, 2016, By Country

Table 14: Metabolic Disorders Drugs Market Size, Percentage Of GDP, Global

Table 15: Per Capita Average Metabolic Disorders Drugs Expenditure, Global

Table 16: Metabolic Disorders Drugs Market Comparison With Macro Economic Factors Across Countries

Table 17: Metabolic Disorders Drugs Market Size, Percentage Of GDP, By Country

Table 18: Per Capita Average Metabolic Disorders Drugs Expenditure, By Country

Table 19: Global Number Of Pharmacists, 2016, By Country

Table 20: Global Metabolic Disorders Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country

Table 21: Global Number Of Pharma Enterprises, 2016, By Country

Table 22: Global Metabolic Disorders Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country

Table 23: Global Average Spending On R&D/Product Development, 2016, By Country

Table 24: Global Metabolic Disorders Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country

Table 25: Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country

Table 26: Global Metabolic Disorders Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country

Table 27: Prevalent Cases Of Hypertension, 2014, By Country

Table 28: Prevalent Cases Of Diabetes, 2015, By Country

Table 29: Global Number Of General Practitioners 2016, By Country

Table 30: Global Metabolic Disorders Drugs Market Revenue Versus Number Of General Practitioners, 2016, By Country

Table 31: Asia-Pacific Metabolic Disorders Drugs Historic Market, 2012-2016

Table 32: Asia-Pacific Metabolic Disorders Drugs Forecast Market, 2016-2020

Table 33: Asia-Pacific Metabolic Disorders Drugs Market, 2016, By Segment

Table 34: China Metabolic Disorders Drugs Historic Market, 2012-2016

Table 35: China Metabolic Disorders Drugs Forecast Market, 2016-2020

Table 36: China Metabolic Disorders Drugs Market, 2016, By Segment

Table 37: China Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Table 38: China Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Table 39: India Metabolic Disorders Drugs Historic Market, 2012-2016

Table 40: India Metabolic Disorders Drugs Forecast Market, 2016-2020

Table 41: India Metabolic Disorders Drugs Market, 2016, By Segment

Table 42: India Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Table 43: India Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Table 44: Japan Metabolic Disorders Drugs Historic Market, 2012-2016

Table 45: Japan Metabolic Disorders Drugs Forecast Market, 2016-2020

Table 46: Japan Metabolic Disorders Drugs Market, 2016, By Segment

Table 47: Japan Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Table 48: Japan Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Table 49: Australia Metabolic Disorders Drugs Historic Market, 2012-2016

Table 50: Australia Metabolic Disorders Drugs Forecast Market, 2016-2020

Table 51: Australia Metabolic Disorders Drugs Market, 2016, By Segment

Table 52: Australia Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Table 53: Australia Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Table 54: Western Europe Metabolic Disorders Drugs Historic Market, 2012-2016

Table 55: Western Europe Metabolic Disorders Drugs Forecast Market, 2016-2020

Table 56: Western Europe Metabolic Disorders Drugs Market, 2016, By Segment

Table 57: UK Metabolic Disorders Drugs Historic Market, 2012-2016

Table 58: UK Metabolic Disorders Drugs Forecast Market, 2016-2020

Table 59: UK Metabolic Disorders Drugs Market, 2016, By Segment

Table 60: UK Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Table 61: UK Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Table 62: Germany Metabolic Disorders Drugs Historic Market, 2012-2016

Table 63: Germany Metabolic Disorders Drugs Forecast Market, 2016-2020

Table 64: Germany Metabolic Disorders Drugs Market, 2016, By Segment

Table 65: Germany Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Table 66: Germany Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Table 67: France Metabolic Disorders Drugs Historic Market, 2012-2016

Table 68: France Metabolic Disorders Drugs Forecast Market, 2016-2020

Table 69: France Metabolic Disorders Drugs Market, 2016, By Segment

Table 70: France Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Table 71: France Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Table 72: Italy Metabolic Disorders Drugs Historic Market, 2012-2016

Table 73: Italy Metabolic Disorders Drugs Forecast Market, 2016-2020

Table 74: Italy Metabolic Disorders Drugs Market, 2016, By Segment

Table 75: Italy Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Table 76: Italy Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Table 77: Spain Metabolic Disorders Drugs Historic Market, 2012-2016

Table 78: Spain Metabolic Disorders Drugs Forecast Market, 2016-2020

Table 79: Spain Metabolic Disorders Drugs Market, 2016, By Segment

Table 80: Spain Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Table 81: Spain Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Table 82: Eastern Europe Metabolic Disorders Drugs Historic Market, 2012-2016

Table 83: Eastern Europe Metabolic Disorders Drugs Forecast Market, 2016-2020

Table 84: Eastern Europe Metabolic Disorders Drugs Market, 2016, By Segment

Table 85: Russia Metabolic Disorders Drugs Historic Market, 2012-2016

Table 86: Russia Metabolic Disorders Drugs Forecast Market, 2016-2020

Table 87: Russia Metabolic Disorders Drugs Market, 2016, By Segment

Table 88: Russia Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Table 89: Russia Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Table 90: North America Metabolic Disorders Drugs Historic Market, 2012-2016

Table 91: North America Metabolic Disorders Drugs Forecast Market, 2016-2020

Table 92: North America Metabolic Disorders Drugs Market, 2016, By Segment

Table 93: USA Metabolic Disorders Drugs Historic Market, 2012-2016

Table 94: USA Metabolic Disorders Drugs Forecast Market, 2016-2020

Table 95: USA Metabolic Disorders Drugs Market, 2016, By Segment

Table 96: USA Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Table 97: USA Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Table 98: South America Metabolic Disorders Drugs Historic Market, 2012-2016

Table 99: South America Metabolic Disorders Drugs Forecast Market, 2016-2020

Table 100: South America Metabolic Disorders Drugs Market, 2016, By Segment

Table 101: Brazil Metabolic Disorders Drugs Historic Market, 2012-2016

Table 102: Brazil Metabolic Disorders Drugs Forecast Market, 2016-2020

Table 103: Brazil Metabolic Disorders Drugs Market, 2016, By Segment

Table 104: Brazil Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Table 105: Brazil Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Table 106: Middle East Metabolic Disorders Drugs Historic Market, 2012-2016

Table 107: Middle East Metabolic Disorders Drugs Forecast Market, 2016-2020

Table 108: Middle East Metabolic Disorders Drugs Market, 2016, By Segment

Table 109: Africa Metabolic Disorders Drugs Historic Market, 2012-2016

Table 110: Africa Metabolic Disorders Drugs Forecast Market, 2016-2020

Table 111: Africa Metabolic Disorders Drugs Market, 2016, By Segment

Table 112: Novo Nordisk Financial Performance

Table 113: Sanofi Financial Performance

Table 114: Merck & Co. Financial Performance

Table 115: Eli Lilly Financial Performance

Table 116: Astrazeneca PLC Financial Performance

Table 117: Pharmaceutical Drugs Market Historic Growth

Table 118: Pharmaceutical Drugs Market Forecast Growth

Table 119: Global Pharmaceutical Drugs Market, 2016, By Region

Table 120: Global Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Region

Table 121: Pharmaceutical Drugs Market, 2016, By Country

Table 122: Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Country

Table 123: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment

Table 124: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment

Table 125: Pharmaceutical Drugs Market Size, Percentage Of GDP, Global

Table 126: Per Capita Average Pharmaceutical Drugs Expenditure, Global

Table 127: Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries

Table 128: Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country

Table 129: Per Capita Average Pharmaceutical Drugs Expenditure, By Country

Table 130: Pharmaceuticals Industry Financial Margins


List Of Table

Figure 1: Global Metabolic Disorders Drugs Historic Market Growth

Figure 2: Global Metabolic Disorders Drugs Forecast Market Growth

Figure 3: Metabolic Disorders Drugs Market Segmentation

Figure 4: Global Metabolic Disorders Drugs Market, 2016, By Segment

Figure 5: Global Metabolic Disorders Drugs Market, 2012-2020, Historic And Forecast, By Segment

Figure 6: Global Metabolic Disorders Drugs Market, 2016, By Region

Figure 7: Global Metabolic Disorders Drugs Market, 2012-2020, Historic And Forecast, By Region

Figure 8: Metabolic Disorders Drugs Market, 2016, By Country

Figure 9: Metabolic Disorders Drugs Market, 2012-2020, Historic And Forecast, By Country

Figure 10: Global Pharmaceutical Market Segments, 2016, By Region

Figure 11: Global Pharmaceutical Drugs Market Segments, 2016, By Region

Figure 12: Global Pharmaceutical Market Segments, 2016, By Country

Figure 13: Global Pharmaceutical Drugs Market Segments, 2016, By Country

Figure 14: Metabolic Disorders Drugs Market Size, Percentage Of GDP, Global

Figure 15: Per Capita Average Metabolic Disorders Drugs Expenditure, Global

Figure 16: Metabolic Disorders Drugs Market Comparison With Macro Economic Factors Across Countries

Figure 17: Metabolic Disorders Drugs Market Size, Percentage Of GDP, By Country

Figure 18: Per Capita Average Metabolic Disorders Drugs Expenditure, By Country

Figure 19: Global Number Of Pharmacists, 2016, By Country

Figure 20: Global Metabolic Disorders Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country

Figure 21: Global Number Of Pharma Enterprises, 2016, By Country

Figure 22: Global Metabolic Disorders Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country

Figure 23: Global Average Spending On R&D/Product Development, 2016, By Country

Figure 24: Global Metabolic Disorders Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country

Figure 25: Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country

Figure 26: Global Metabolic Disorders Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country

Figure 27: Prevalent Cases Of Hypertension, 2014, By Country

Figure 28: Prevalent Cases Of Diabetes, 2015, By Country

Figure 29: Global Number Of General Practitioners 2016, By Country

Figure 30: Global Metabolic Disorders Drugs Market Revenue Versus Number Of General Practitioners, 2016, By Country

Figure 31: Asia-Pacific Metabolic Disorders Drugs Historic Market, 2012-2016

Figure 32: Asia-Pacific Metabolic Disorders Drugs Forecast Market, 2016-2020

Figure 33: Asia-Pacific Metabolic Disorders Drugs Market, 2016, By Segment

Figure 34: China Metabolic Disorders Drugs Historic Market, 2012-2016

Figure 35: China Metabolic Disorders Drugs Forecast Market, 2016-2020

Figure 36: China Metabolic Disorders Drugs Market, 2016, By Segment

Figure 37: China Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Figure 38: China Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Figure 39: India Metabolic Disorders Drugs Historic Market, 2012-2016

Figure 40: India Metabolic Disorders Drugs Forecast Market, 2016-2020

Figure 41: India Metabolic Disorders Drugs Market, 2016, By Segment

Figure 42: India Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Figure 43: India Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Figure 44: Japan Metabolic Disorders Drugs Historic Market, 2012-2016

Figure 45: Japan Metabolic Disorders Drugs Forecast Market, 2016-2020

Figure 46: Japan Metabolic Disorders Drugs Market, 2016, By Segment

Figure 47: Japan Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Figure 48: Japan Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Figure 49: Australia Metabolic Disorders Drugs Historic Market, 2012-2016

Figure 50: Australia Metabolic Disorders Drugs Forecast Market, 2016-2020

Figure 51: Australia Metabolic Disorders Drugs Market, 2016, By Segment

Figure 52: Australia Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Figure 53: Australia Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Figure 54: Western Europe Metabolic Disorders Drugs Historic Market, 2012-2016

Figure 55: Western Europe Metabolic Disorders Drugs Forecast Market, 2016-2020

Figure 56: Western Europe Metabolic Disorders Drugs Market, 2016, By Segment

Figure 57: UK Metabolic Disorders Drugs Historic Market, 2012-2016

Figure 58: UK Metabolic Disorders Drugs Forecast Market, 2016-2020

Figure 59: UK Metabolic Disorders Drugs Market, 2016, By Segment

Figure 60: UK Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Figure 61: UK Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Figure 62: Germany Metabolic Disorders Drugs Historic Market, 2012-2016

Figure 63: Germany Metabolic Disorders Drugs Forecast Market, 2016-2020

Figure 64: Germany Metabolic Disorders Drugs Market, 2016, By Segment

Figure 65: Germany Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Figure 66: Germany Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Figure 67: France Metabolic Disorders Drugs Historic Market, 2012-2016

Figure 68: France Metabolic Disorders Drugs Forecast Market, 2016-2020

Figure 69: France Metabolic Disorders Drugs Market, 2016, By Segment

Figure 70: France Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Figure 71: France Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Figure 72: Italy Metabolic Disorders Drugs Historic Market, 2012-2016

Figure 73: Italy Metabolic Disorders Drugs Forecast Market, 2016-2020

Figure 74: Italy Metabolic Disorders Drugs Market, 2016, By Segment

Figure 75: Italy Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Figure 76: Italy Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Figure 77: Spain Metabolic Disorders Drugs Historic Market, 2012-2016

Figure 78: Spain Metabolic Disorders Drugs Forecast Market, 2016-2020

Figure 79: Spain Metabolic Disorders Drugs Market, 2016, By Segment

Figure 80: Spain Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Figure 81: Spain Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Figure 82: Eastern Europe Metabolic Disorders Drugs Historic Market, 2012-2016

Figure 83: Eastern Europe Metabolic Disorders Drugs Forecast Market, 2016-2020

Figure 84: Eastern Europe Metabolic Disorders Drugs Market, 2016, By Segment

Figure 85: Russia Metabolic Disorders Drugs Historic Market, 2012-2016

Figure 86: Russia Metabolic Disorders Drugs Forecast Market, 2016-2020

Figure 87: Russia Metabolic Disorders Drugs Market, 2016, By Segment

Figure 88: Russia Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Figure 89: Russia Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Figure 90: North America Metabolic Disorders Drugs Historic Market, 2012-2016

Figure 91: North America Metabolic Disorders Drugs Forecast Market, 2016-2020

Figure 92: North America Metabolic Disorders Drugs Market, 2016, By Segment

Figure 93: USA Metabolic Disorders Drugs Historic Market, 2012-2016

Figure 94: USA Metabolic Disorders Drugs Forecast Market, 2016-2020

Figure 95: USA Metabolic Disorders Drugs Market, 2016, By Segment

Figure 96: USA Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Figure 97: USA Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Figure 98: South America Metabolic Disorders Drugs Historic Market, 2012-2016

Figure 99: South America Metabolic Disorders Drugs Forecast Market, 2016-2020

Figure 100: South America Metabolic Disorders Drugs Market, 2016, By Segment

Figure 101: Brazil Metabolic Disorders Drugs Historic Market, 2012-2016

Figure 102: Brazil Metabolic Disorders Drugs Forecast Market, 2016-2020

Figure 103: Brazil Metabolic Disorders Drugs Market, 2016, By Segment

Figure 104: Brazil Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Figure 105: Brazil Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Figure 106: Middle East Metabolic Disorders Drugs Historic Market, 2012-2016

Figure 107: Middle East Metabolic Disorders Drugs Forecast Market, 2016-2020

Figure 108: Middle East Metabolic Disorders Drugs Market, 2016, By Segment

Figure 109: Africa Metabolic Disorders Drugs Historic Market, 2012-2016

Figure 110: Africa Metabolic Disorders Drugs Forecast Market, 2016-2020

Figure 111: Africa Metabolic Disorders Drugs Market, 2016, By Segment

Figure 112: Novo Nordisk Financial Performance

Figure 113: Sanofi Financial Performance

Figure 114: Merck & Co. Financial Performance

Figure 115: Eli Lilly Financial Performance

Figure 116: Astrazeneca PLC Financial Performance

Figure 117: Pharmaceutical Drugs Market Historic Growth

Figure 118: Pharmaceutical Drugs Market Forecast Growth

Figure 119: Global Pharmaceutical Drugs Market, 2016, By Region

Figure 120: Global Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Region

Figure 121: Pharmaceutical Drugs Market, 2016, By Country

Figure 122: Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Country

Figure 123: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment

Figure 124: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment

Figure 125: Pharmaceutical Drugs Market Size, Percentage Of GDP, Global

Figure 126: Per Capita Average Pharmaceutical Drugs Expenditure, Global

Figure 127: Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries

Figure 128: Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country

Figure 129: Per Capita Average Pharmaceutical Drugs Expenditure, By Country

Figure 130: Pharmaceuticals Industry Financial Margins

Licence Rights

  • Single User License (for access by one person)
  • Site License (for access of one office location of a company)
  • Corporate License (allow access by all staff of the company)

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Anti-Diabetics, Anti-Thyroid Drugs, Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)


Companies

Novo Nordisk, Sanofi, Merck & Co., Eli Lilly, and AstraZeneca PLC

Company Profile

Company Profile Title

Metabolic disorders drugs market covers medications that are used in the treatment of diseases such as diabetes, thyroid, hyperparathyroidism, hypopituitarism, hypoadrenalism and other metabolic diseases. Some of the major drugs used in the treatment metabolic diseases are Lantus (type 1 and 2 diabetes), Januvia (diabetes), and other drugs.

The global metabolic disorders drugs market was estimated to be around $80 billion as of 2016. The metabolic disorders drugs market made up around 7% of the overall pharmaceuticals market in 2016. The metabolic disorders drugs market was the seventh largest market in the global pharmaceutical market in 2016.

Acquisitions

Strategic acquisitions of small companies by market leaders in the market to strengthen their market position is one of the major trend in the market. For instance, in August 2015 Novo Nordisk acquired Calibrium LLC and MB2 LLC, a US based biopharmaceutical research companies. Through the acquisitions Novo Nordisk focuses on expanding its obesity and diabetes product line by integrating Calibrium LLC and MB2 LLC companies.

The Metabolic Disorders Drugs Market Global Report provides strategists, marketers and senior management with the critical information they need to assess the global metabolic disorders drugs sector.

Reasons to Purchase

Outperform competitors using accurate up to date demand-side dynamics information.

Identify growth segments for investment.

Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.

Create regional and country strategies on the basis of local data and analysis.

Stay abreast of the latest customer and market research findings

Benchmark performance against key competitors.

Develop strategies based on likely future developments.

Utilize the relationships between key data sets for superior strategizing.

Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Gain a global perspective on the development of the market.

Report will be updated with the latest data and delivered to you within 3-5 working days of order.

Description:

Where is the largest and fastest growing market for the metabolic disorders drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The metabolic disorders drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider pharmaceutical drugs market, and compares it with other markets.

The market characteristics section of the report defines and explains the market.

The market size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.

Market segmentations break down market into sub markets.

The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.

Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.

The trends and strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.

The metabolic disorders drugs market section of the report gives context. It compares the metabolic disorders drugs market with other segments of the pharmaceutical drugs market by size and growth, historic and forecast. It analyses Expenditure Per Capita, The Metabolic Disorders Drugs Indicators Comparison.

The industry metrics section looks at critical drivers including patient numbers (epidemiology) hospital beds and specialist physicians while the macro-economic section looks at the market in relation to the overall economy.

Scope

Markets Covered: Anti-Diabetics, Anti-Thyroid Drugs, Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)

Companies Mentioned: Novo Nordisk, Sanofi, Merck & Co., Eli Lilly, and AstraZeneca PLC

Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.

Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa

Time series: Five years historic and forecast.

Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, The Metabolic Disorders Drugs Indicators Comparison.

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

READ MORE

Scope

1. Metabolic Disorders Drugs Market Characteristics;

2. Metabolic Disorders Drugs Market Size And Growth;

2.1. Historic Market Growth; 2.1.1. Drivers Of The Market; 2.1.2. Restraints On The Market; 2.2. Forecast Market Growth; 2.2.1. Drivers Of The Market; 2.2.2. Restraints On The Market;

3. Pestle Analysis;

3.1. Political; 3.2. Economic; 3.3. Social; 3.4. Technological; 3.5. Legal; 3.6. Environmental;

4. Metabolic Disorders Drugs Market Customer Information;

5. Metabolic Disorders Drugs Market Segmentation;

5.1. Global Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 5.2. Global Metabolic Disorders Drugs Market, 2012-2020, Historic And Forecast, By Segment; 5.3 Global Metabolic Disorders Drugs Market Trends And Strategies;

6. Metabolic Disorders Drugs Market Regional And Country Analysis;

6.1. Global Metabolic Disorders Drugs Market, 2016, By Region; 6.2. Global Metabolic Disorders Drugs Market, 2012-2020, Historic And Forecast, By Region; 6.3. Metabolic Disorders Drugs Market, 2016, By Country; 6.4. Metabolic Disorders Drugs Market, 2012-2020, Historic And Forecast, By Country; 6.5. Global Pharmaceutical Market Segments, 2016, By Region; 6.6. Global Pharmaceutical Drugs Market Segments, 2016, By Region; 6.7. Global Pharmaceutical Market Segments, 2016, By Country; 6.8.Global Pharmaceutical Drugs Market Segments, 2016, By Country;

7. Global Metabolic Disorders Drugs Market Comparison With Macro Economic Factors;

7.1. Metabolic Disorders Drugs Market Size, Percentage Of GDP, Global; 7.2. Per Capita Average Metabolic Disorders Drugs Expenditure, Global;

8. Metabolic Disorders Drugs Market Comparison With Macro Economic Factors Across Countries;

8.1. Metabolic Disorders Drugs Market Size, Percentage Of GDP, By Country; 8.2. Per Capita Average Metabolic Disorders Drugs Expenditure, By Country;

9. Metabolic Disorders Drugs Market Comparison With Industry Metrics;

9.1. Global Number Of Pharmacists, 2016, By Country; 9.2. Global Metabolic Disorders Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country; 9.3. Global Number Of Pharma Enterprises, 2016, By Country; 9.4. Global Metabolic Disorders Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country; 9.5. Global Average Spending On R&D/Product Development, 2016, By Country; 9.6. Global Metabolic Disorders Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country; 9.7. Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.8. Global Metabolic Disorders Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.9. Prevalent Cases Of Hypertension, 2014, By Country; 9.10. Prevalent Cases Of Diabetes, 2015, By Country; 9.11. Global Number Of General Practitioners 2016, By Country; 9.12. Global Metabolic Disorders Drugs Market Revenue Versus Number Of General Practitioners, 2016, By Country;

10. Asia-Pacific Metabolic Disorders Drugs Market;

10.1.1. Asia-Pacific Metabolic Disorders Drugs Market Overview; 10.1.2. Asia-Pacific Metabolic Disorders Drugs Historic Market, 2012-2016; 10.1.3. Asia-Pacific Metabolic Disorders Drugs Forecast Market, 2016-2020; 10.1.4. Asia-Pacific Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 10.2. Asia-Pacific Metabolic Disorders Drugs Market: Country Analysis; 10.3. China Metabolic Disorders Drugs Market; 10.3.1. China Metabolic Disorders Drugs Market Overview; 10.3.2. China Metabolic Disorders Drugs Historic Market, 2012-2016; 10.3.3. China Metabolic D4isorders Forecast Market, 2016-2020; 10.3.4. China Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 10.3.5. China Metabolic Disorders Drugs Percentage Of GDP, 2012-2020; 10.3.6. China Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020; 10.4. India Metabolic Disorders Drugs Market; 10.4.1. India Metabolic Disorders Drugs Market Overview; 10.4.2. India Metabolic Disorders Drugs Historic Market, 2012-2016; 10.4.3. India Metabolic Disorders Drugs Forecast Market, 2016-2020; 10.4.4. India Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 10.4.5. India Metabolic Disorders Drugs Percentage Of GDP, 2012-2020; 10.4.6. India Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020; 10.5. Japan Metabolic Disorders Drugs Market; 10.5.1. Japan Metabolic Disorders Drugs Market Overview; 10.5.2. Japan Metabolic Disorders Drugs Historic Market, 2012-2016; 10.5.3. Japan Metabolic Disorders Drugs Forecast Market, 2016-2020; 10.5.4. Japan Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 10.5.5. Japan Metabolic Disorders Drugs Percentage Of GDP, 2012-2020; 10.5.6. Japan Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020; 10.6. Australia Metabolic Disorders Drugs Market; 10.6.1. Australia Metabolic Disorders Drugs Historic Market, 2012-2016; 10.6.2. Australia Metabolic Disorders Drugs Forecast Market, 2016-2020; 10.6.3. Australia Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 10.6.4. Australia Metabolic Disorders Drugs Percentage Of GDP, 2012-2020; 10.6.5. Australia Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020;

11. Western Europe Metabolic Disorders Drugs Market;

11.1.1. Western Europe Metabolic Disorders Drugs Market Overview; 11.1.2. Western Europe Metabolic Disorders Drugs Historic Market, 2012-2016; 11.1.3. Western Europe Metabolic Disorders Drugs Forecast Market, 2016-2020; 11.1.4. Western Europe Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 11.2. Western Europe Metabolic Disorders Drugs Market: Country Analysis; 11.3. UK Metabolic Disorders Drugs Market; 11.3.1. UK Metabolic Disorders Drugs Market Overview; 11.3.2. UK Metabolic Disorders Drugs Historic Market, 2012-2016; 11.3.3. UK Metabolic Disorders Drugs Forecast Market, 2016-2020; 11.3.4. UK Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 11.3.5. UK Metabolic Disorders Drugs Percentage Of GDP, 2012-2020; 11.3.6. UK Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020; 11.4. Germany Metabolic Disorders Drugs Market; 11.4.1. Germany Metabolic Disorders Drugs Historic Market, 2012-2016; 11.4.2. Germany Metabolic Disorders Drugs Forecast Market, 2016-2020; 11.4.3. Germany Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 11.4.4 Germany Metabolic Disorders Drugs Percentage Of GDP, 2012-2020; 11.4.5 Germany Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020; 11.5 France Metabolic Disorders Drugs Market; 11.5.1 France Metabolic Disorders Drugs Historic Market, 2012-2016; 11.5.2 France Metabolic Disorders Drugs Forecast Market, 2016-2020; 11.5.3 France Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 11.5.4 France Metabolic Disorders Drugs Percentage Of GDP, 2012-2020; 11.5.5 France Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020; 11.6. Italy Metabolic Disorders Drugs Market; 11.6.1. Italy Metabolic Disorders Drugs Historic Market, 2012-2016; 11.6.2. Italy Metabolic Disorders Drugs Forecast Market, 2016-2020; 11.6.3. Italy Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 11.6.4. Italy Metabolic Disorders Drugs Percentage Of GDP, 2012-2020; 11.6.5. Italy Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020; 11.7. Spain Metabolic Disorders Drugs Market; 11.7.1. Spain Metabolic Disorders Drugs Historic Market, 2012-2016; 11.7.2. Spain Metabolic Disorders Drugs Forecast Market, 2016-2020; 11.7.3. Spain Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 11.7.4. Spain Metabolic Disorders Drugs Percentage Of GDP, 2012-2020; 11.7.5. Spain Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020;

12. Eastern Europe Metabolic Disorders Drugs Market;

12.1.1. Eastern Europe Metabolic Disorders Drugs Market Overview; 12.1.2. Eastern Europe Metabolic Disorders Drugs Historic Market, 2012-2016; 12.1.3. Eastern Europe Metabolic Disorders Drugs Forecast Market, 2016-2020; 12.1.4 Eastern Europe Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 12.2. Eastern Europe Metabolic Disorders Drugs Market: Country Analysis; 12.3. Russia Metabolic Disorders Drugs Market; 12.3.1. Russia Metabolic Disorders Drugs Historic Market, 2012-2016; 12.3.2. Russia Metabolic Disorders Drugs Forecast Market, 2016-2020; 12.3.3. Russia Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 12.3.4. Russia Metabolic Disorders Drugs Percentage Of GDP, 2012-2020; 12.3.5. Russia Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020;

13. North America Metabolic Disorders Drugs Market;

13.1.1. North America Metabolic Disorders Drugs Market Overview; 13.1.2. North America Metabolic Disorders Drugs Historic Market, 2012-2016; 13.1.3. North America Metabolic Disorders Drugs Forecast Market, 2016-2020; 13.1.4. North America Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 13.2. North America Metabolic Disorders Drugs Market: Country Analysis; 13.3. USA Metabolic Disorders Drugs Market; 13.3.1. USA Metabolic Disorders Drugs Historic Market, 2012-2016; 13.3.2. USA Metabolic Disorders Drugs Forecast Market, 2016-2020; 13.3.3 USA Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 13.3.4. USA Metabolic Disorders Drugs Percentage Of GDP, 2012-2020; 13.3.5. USA Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020;

14. South America Metabolic Disorders Drugs Market;

14.1.1. South America Metabolic Disorders Drugs Market Overview; 14.1.2. South America Metabolic Disorders Drugs Historic Market, 2012-2016; 14.1.3. South America Metabolic Disorders Drugs Forecast Market, 2016-2020; 14.1.4. South America Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 14.2. South America Metabolic Disorders Drugs Market: Country Analysis; 14.3. Brazil Metabolic Disorders Drugs Market; 14.3.1. Brazil Metabolic Disorders Drugs Historic Market, 2012-2016; 14.3.2. Brazil Metabolic Disorders Drugs Forecast Market, 2016-2020; 14.3.3. Brazil Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism); 14.3.4. Brazil Metabolic Disorders Drugs Percentage Of GDP, 2012-2020; 14.3.5. Brazil Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020;

15. Middle East Metabolic Disorders Drugs Market;

15.1.1. Middle East Metabolic Disorders Drugs Market Overview; 15.1.2. Middle East Metabolic Disorders Drugs Historic Market, 2012-2016; 15.1.3. Middle East Metabolic Disorders Drugs Forecast Market, 2016-2020; 15.1.4. Middle East Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism);

16. Africa Metabolic Disorders Drugs Market;

16.1.1. Africa Metabolic Disorders Drugs Market Overview; 16.1.2. Africa Metabolic Disorders Drugs Historic Market, 2012-2016; 16.1.3. Africa Metabolic Disorders Drugs Forecast Market, 2016-2020; 16.1.4. Africa Metabolic Disorders Drugs Market, 2016, By Segment; Anti-Diabetics; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism);

17. Metabolic Disorders Drugs Market Competitive Landscape;

17.1. Company Profiles; 17.2. Novo Nordisk; 17.2.1. Overview; 17.2.2. Products And Services; 17.2.3. Strategy; 17.2.4. Financial Performance; 17.3. Sanofi; 17.3.1. Overview; 17.3.2. Products And Services; 17.3.3. Strategy; 17.3.4. Financial Performance; 17.4. Merck & Co.; 17.4.1. Overview; 17.4.2. Products And Services; 17.4.3. Strategy; 17.4.4. Financial Performance; 17.5. Eli Lilly; 17.5.1. Overview; 17.5.2. Products And Services; 17.5.3. Strategy; 17.5.4. Financial Performance; 17.6. Astrazeneca PLC; 17.6.1. Overview; 17.6.2. Products And Services; 17.6.3. Strategy; 17.6.4. Financial Performance;

18. Key Mergers And Acquisitions In The Metabolic Disorders Drugs Market;

19. Market Background: Pharmaceutical Drugs Market;

19.1.1. Pharmaceutical Drugs Market Characteristics; 19.1.2. Pharmaceutical Drugs Market Historic Growth; 19.1.2.1. Drivers Of The Market; 19.1.2.2. Restraints Of The Market; 19.1.3. Pharmaceutical Drugs Market Forecast Growth; 19.1.3.1. Drivers Of The Market; 19.1.3.2. Restraints Of The Market; 19.1.4. Pharmaceutical Drugs Trends And Strategies; 19.2. Pharmaceutical Drugs Market Regional And Country Analysis; 19.2.1. Global Pharmaceutical Drugs Market, 2016, By Region; 19.2.2. Global Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Region; 19.2.3. Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Country; 19.2.4. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment; 19.2.5. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment; 19.3. Global Pharmaceutical Drugs Market Comparison With Macro Economic Factors; 19.3.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, Global; 19.3.2. Per Capita Average Pharmaceutical Drugs Expenditure, Global; 19.4. Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries; 19.4.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country; 19.4.2. Per Capita Average Pharmaceutical Drugs Expenditure, By Country; 19.5. Key Mergers And Acquisitions In The Pharmaceutical Drugs Market;

20. Pharmaceuticals Industry Financial Margins;

21. Appendix;

21.1. NAICS Definitions Of Industry Covered In This Report; 21.2. Abbreviations; 21.3. Currencies; 21.4. Research Inquiries; 21.5. The Business Research Company; 21.6. Copyright And Disclaimer


List Of Figure

Table 1: Global Metabolic Disorders Drugs Historic Market Growth

Table 2: Global Metabolic Disorders Drugs Forecast Market Growth

Table 3: Metabolic Disorders Drugs Market Segmentation

Table 4: Global Metabolic Disorders Drugs Market, 2016, By Segment

Table 5: Global Metabolic Disorders Drugs Market, 2012-2020, Historic And Forecast, By Segment

Table 6: Global Metabolic Disorders Drugs Market, 2016, By Region

Table 7: Global Metabolic Disorders Drugs Market, 2012-2020, Historic And Forecast, By Region

Table 8: Metabolic Disorders Drugs Market, 2016, By Country

Table 9: Metabolic Disorders Drugs Market, 2012-2020, Historic And Forecast, By Country

Table 10: Global Pharmaceutical Market Segments, 2016, By Region

Table 11: Global Pharmaceutical Drugs Market Segments, 2016, By Region

Table 12: Global Pharmaceutical Market Segments, 2016, By Country

Table 13: Global Pharmaceutical Drugs Market Segments, 2016, By Country

Table 14: Metabolic Disorders Drugs Market Size, Percentage Of GDP, Global

Table 15: Per Capita Average Metabolic Disorders Drugs Expenditure, Global

Table 16: Metabolic Disorders Drugs Market Comparison With Macro Economic Factors Across Countries

Table 17: Metabolic Disorders Drugs Market Size, Percentage Of GDP, By Country

Table 18: Per Capita Average Metabolic Disorders Drugs Expenditure, By Country

Table 19: Global Number Of Pharmacists, 2016, By Country

Table 20: Global Metabolic Disorders Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country

Table 21: Global Number Of Pharma Enterprises, 2016, By Country

Table 22: Global Metabolic Disorders Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country

Table 23: Global Average Spending On R&D/Product Development, 2016, By Country

Table 24: Global Metabolic Disorders Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country

Table 25: Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country

Table 26: Global Metabolic Disorders Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country

Table 27: Prevalent Cases Of Hypertension, 2014, By Country

Table 28: Prevalent Cases Of Diabetes, 2015, By Country

Table 29: Global Number Of General Practitioners 2016, By Country

Table 30: Global Metabolic Disorders Drugs Market Revenue Versus Number Of General Practitioners, 2016, By Country

Table 31: Asia-Pacific Metabolic Disorders Drugs Historic Market, 2012-2016

Table 32: Asia-Pacific Metabolic Disorders Drugs Forecast Market, 2016-2020

Table 33: Asia-Pacific Metabolic Disorders Drugs Market, 2016, By Segment

Table 34: China Metabolic Disorders Drugs Historic Market, 2012-2016

Table 35: China Metabolic Disorders Drugs Forecast Market, 2016-2020

Table 36: China Metabolic Disorders Drugs Market, 2016, By Segment

Table 37: China Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Table 38: China Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Table 39: India Metabolic Disorders Drugs Historic Market, 2012-2016

Table 40: India Metabolic Disorders Drugs Forecast Market, 2016-2020

Table 41: India Metabolic Disorders Drugs Market, 2016, By Segment

Table 42: India Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Table 43: India Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Table 44: Japan Metabolic Disorders Drugs Historic Market, 2012-2016

Table 45: Japan Metabolic Disorders Drugs Forecast Market, 2016-2020

Table 46: Japan Metabolic Disorders Drugs Market, 2016, By Segment

Table 47: Japan Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Table 48: Japan Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Table 49: Australia Metabolic Disorders Drugs Historic Market, 2012-2016

Table 50: Australia Metabolic Disorders Drugs Forecast Market, 2016-2020

Table 51: Australia Metabolic Disorders Drugs Market, 2016, By Segment

Table 52: Australia Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Table 53: Australia Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Table 54: Western Europe Metabolic Disorders Drugs Historic Market, 2012-2016

Table 55: Western Europe Metabolic Disorders Drugs Forecast Market, 2016-2020

Table 56: Western Europe Metabolic Disorders Drugs Market, 2016, By Segment

Table 57: UK Metabolic Disorders Drugs Historic Market, 2012-2016

Table 58: UK Metabolic Disorders Drugs Forecast Market, 2016-2020

Table 59: UK Metabolic Disorders Drugs Market, 2016, By Segment

Table 60: UK Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Table 61: UK Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Table 62: Germany Metabolic Disorders Drugs Historic Market, 2012-2016

Table 63: Germany Metabolic Disorders Drugs Forecast Market, 2016-2020

Table 64: Germany Metabolic Disorders Drugs Market, 2016, By Segment

Table 65: Germany Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Table 66: Germany Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Table 67: France Metabolic Disorders Drugs Historic Market, 2012-2016

Table 68: France Metabolic Disorders Drugs Forecast Market, 2016-2020

Table 69: France Metabolic Disorders Drugs Market, 2016, By Segment

Table 70: France Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Table 71: France Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Table 72: Italy Metabolic Disorders Drugs Historic Market, 2012-2016

Table 73: Italy Metabolic Disorders Drugs Forecast Market, 2016-2020

Table 74: Italy Metabolic Disorders Drugs Market, 2016, By Segment

Table 75: Italy Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Table 76: Italy Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Table 77: Spain Metabolic Disorders Drugs Historic Market, 2012-2016

Table 78: Spain Metabolic Disorders Drugs Forecast Market, 2016-2020

Table 79: Spain Metabolic Disorders Drugs Market, 2016, By Segment

Table 80: Spain Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Table 81: Spain Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Table 82: Eastern Europe Metabolic Disorders Drugs Historic Market, 2012-2016

Table 83: Eastern Europe Metabolic Disorders Drugs Forecast Market, 2016-2020

Table 84: Eastern Europe Metabolic Disorders Drugs Market, 2016, By Segment

Table 85: Russia Metabolic Disorders Drugs Historic Market, 2012-2016

Table 86: Russia Metabolic Disorders Drugs Forecast Market, 2016-2020

Table 87: Russia Metabolic Disorders Drugs Market, 2016, By Segment

Table 88: Russia Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Table 89: Russia Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Table 90: North America Metabolic Disorders Drugs Historic Market, 2012-2016

Table 91: North America Metabolic Disorders Drugs Forecast Market, 2016-2020

Table 92: North America Metabolic Disorders Drugs Market, 2016, By Segment

Table 93: USA Metabolic Disorders Drugs Historic Market, 2012-2016

Table 94: USA Metabolic Disorders Drugs Forecast Market, 2016-2020

Table 95: USA Metabolic Disorders Drugs Market, 2016, By Segment

Table 96: USA Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Table 97: USA Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Table 98: South America Metabolic Disorders Drugs Historic Market, 2012-2016

Table 99: South America Metabolic Disorders Drugs Forecast Market, 2016-2020

Table 100: South America Metabolic Disorders Drugs Market, 2016, By Segment

Table 101: Brazil Metabolic Disorders Drugs Historic Market, 2012-2016

Table 102: Brazil Metabolic Disorders Drugs Forecast Market, 2016-2020

Table 103: Brazil Metabolic Disorders Drugs Market, 2016, By Segment

Table 104: Brazil Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Table 105: Brazil Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Table 106: Middle East Metabolic Disorders Drugs Historic Market, 2012-2016

Table 107: Middle East Metabolic Disorders Drugs Forecast Market, 2016-2020

Table 108: Middle East Metabolic Disorders Drugs Market, 2016, By Segment

Table 109: Africa Metabolic Disorders Drugs Historic Market, 2012-2016

Table 110: Africa Metabolic Disorders Drugs Forecast Market, 2016-2020

Table 111: Africa Metabolic Disorders Drugs Market, 2016, By Segment

Table 112: Novo Nordisk Financial Performance

Table 113: Sanofi Financial Performance

Table 114: Merck & Co. Financial Performance

Table 115: Eli Lilly Financial Performance

Table 116: Astrazeneca PLC Financial Performance

Table 117: Pharmaceutical Drugs Market Historic Growth

Table 118: Pharmaceutical Drugs Market Forecast Growth

Table 119: Global Pharmaceutical Drugs Market, 2016, By Region

Table 120: Global Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Region

Table 121: Pharmaceutical Drugs Market, 2016, By Country

Table 122: Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Country

Table 123: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment

Table 124: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment

Table 125: Pharmaceutical Drugs Market Size, Percentage Of GDP, Global

Table 126: Per Capita Average Pharmaceutical Drugs Expenditure, Global

Table 127: Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries

Table 128: Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country

Table 129: Per Capita Average Pharmaceutical Drugs Expenditure, By Country

Table 130: Pharmaceuticals Industry Financial Margins


List Of Table

Figure 1: Global Metabolic Disorders Drugs Historic Market Growth

Figure 2: Global Metabolic Disorders Drugs Forecast Market Growth

Figure 3: Metabolic Disorders Drugs Market Segmentation

Figure 4: Global Metabolic Disorders Drugs Market, 2016, By Segment

Figure 5: Global Metabolic Disorders Drugs Market, 2012-2020, Historic And Forecast, By Segment

Figure 6: Global Metabolic Disorders Drugs Market, 2016, By Region

Figure 7: Global Metabolic Disorders Drugs Market, 2012-2020, Historic And Forecast, By Region

Figure 8: Metabolic Disorders Drugs Market, 2016, By Country

Figure 9: Metabolic Disorders Drugs Market, 2012-2020, Historic And Forecast, By Country

Figure 10: Global Pharmaceutical Market Segments, 2016, By Region

Figure 11: Global Pharmaceutical Drugs Market Segments, 2016, By Region

Figure 12: Global Pharmaceutical Market Segments, 2016, By Country

Figure 13: Global Pharmaceutical Drugs Market Segments, 2016, By Country

Figure 14: Metabolic Disorders Drugs Market Size, Percentage Of GDP, Global

Figure 15: Per Capita Average Metabolic Disorders Drugs Expenditure, Global

Figure 16: Metabolic Disorders Drugs Market Comparison With Macro Economic Factors Across Countries

Figure 17: Metabolic Disorders Drugs Market Size, Percentage Of GDP, By Country

Figure 18: Per Capita Average Metabolic Disorders Drugs Expenditure, By Country

Figure 19: Global Number Of Pharmacists, 2016, By Country

Figure 20: Global Metabolic Disorders Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country

Figure 21: Global Number Of Pharma Enterprises, 2016, By Country

Figure 22: Global Metabolic Disorders Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country

Figure 23: Global Average Spending On R&D/Product Development, 2016, By Country

Figure 24: Global Metabolic Disorders Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country

Figure 25: Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country

Figure 26: Global Metabolic Disorders Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country

Figure 27: Prevalent Cases Of Hypertension, 2014, By Country

Figure 28: Prevalent Cases Of Diabetes, 2015, By Country

Figure 29: Global Number Of General Practitioners 2016, By Country

Figure 30: Global Metabolic Disorders Drugs Market Revenue Versus Number Of General Practitioners, 2016, By Country

Figure 31: Asia-Pacific Metabolic Disorders Drugs Historic Market, 2012-2016

Figure 32: Asia-Pacific Metabolic Disorders Drugs Forecast Market, 2016-2020

Figure 33: Asia-Pacific Metabolic Disorders Drugs Market, 2016, By Segment

Figure 34: China Metabolic Disorders Drugs Historic Market, 2012-2016

Figure 35: China Metabolic Disorders Drugs Forecast Market, 2016-2020

Figure 36: China Metabolic Disorders Drugs Market, 2016, By Segment

Figure 37: China Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Figure 38: China Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Figure 39: India Metabolic Disorders Drugs Historic Market, 2012-2016

Figure 40: India Metabolic Disorders Drugs Forecast Market, 2016-2020

Figure 41: India Metabolic Disorders Drugs Market, 2016, By Segment

Figure 42: India Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Figure 43: India Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Figure 44: Japan Metabolic Disorders Drugs Historic Market, 2012-2016

Figure 45: Japan Metabolic Disorders Drugs Forecast Market, 2016-2020

Figure 46: Japan Metabolic Disorders Drugs Market, 2016, By Segment

Figure 47: Japan Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Figure 48: Japan Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Figure 49: Australia Metabolic Disorders Drugs Historic Market, 2012-2016

Figure 50: Australia Metabolic Disorders Drugs Forecast Market, 2016-2020

Figure 51: Australia Metabolic Disorders Drugs Market, 2016, By Segment

Figure 52: Australia Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Figure 53: Australia Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Figure 54: Western Europe Metabolic Disorders Drugs Historic Market, 2012-2016

Figure 55: Western Europe Metabolic Disorders Drugs Forecast Market, 2016-2020

Figure 56: Western Europe Metabolic Disorders Drugs Market, 2016, By Segment

Figure 57: UK Metabolic Disorders Drugs Historic Market, 2012-2016

Figure 58: UK Metabolic Disorders Drugs Forecast Market, 2016-2020

Figure 59: UK Metabolic Disorders Drugs Market, 2016, By Segment

Figure 60: UK Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Figure 61: UK Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Figure 62: Germany Metabolic Disorders Drugs Historic Market, 2012-2016

Figure 63: Germany Metabolic Disorders Drugs Forecast Market, 2016-2020

Figure 64: Germany Metabolic Disorders Drugs Market, 2016, By Segment

Figure 65: Germany Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Figure 66: Germany Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Figure 67: France Metabolic Disorders Drugs Historic Market, 2012-2016

Figure 68: France Metabolic Disorders Drugs Forecast Market, 2016-2020

Figure 69: France Metabolic Disorders Drugs Market, 2016, By Segment

Figure 70: France Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Figure 71: France Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Figure 72: Italy Metabolic Disorders Drugs Historic Market, 2012-2016

Figure 73: Italy Metabolic Disorders Drugs Forecast Market, 2016-2020

Figure 74: Italy Metabolic Disorders Drugs Market, 2016, By Segment

Figure 75: Italy Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Figure 76: Italy Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Figure 77: Spain Metabolic Disorders Drugs Historic Market, 2012-2016

Figure 78: Spain Metabolic Disorders Drugs Forecast Market, 2016-2020

Figure 79: Spain Metabolic Disorders Drugs Market, 2016, By Segment

Figure 80: Spain Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Figure 81: Spain Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Figure 82: Eastern Europe Metabolic Disorders Drugs Historic Market, 2012-2016

Figure 83: Eastern Europe Metabolic Disorders Drugs Forecast Market, 2016-2020

Figure 84: Eastern Europe Metabolic Disorders Drugs Market, 2016, By Segment

Figure 85: Russia Metabolic Disorders Drugs Historic Market, 2012-2016

Figure 86: Russia Metabolic Disorders Drugs Forecast Market, 2016-2020

Figure 87: Russia Metabolic Disorders Drugs Market, 2016, By Segment

Figure 88: Russia Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Figure 89: Russia Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Figure 90: North America Metabolic Disorders Drugs Historic Market, 2012-2016

Figure 91: North America Metabolic Disorders Drugs Forecast Market, 2016-2020

Figure 92: North America Metabolic Disorders Drugs Market, 2016, By Segment

Figure 93: USA Metabolic Disorders Drugs Historic Market, 2012-2016

Figure 94: USA Metabolic Disorders Drugs Forecast Market, 2016-2020

Figure 95: USA Metabolic Disorders Drugs Market, 2016, By Segment

Figure 96: USA Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Figure 97: USA Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Figure 98: South America Metabolic Disorders Drugs Historic Market, 2012-2016

Figure 99: South America Metabolic Disorders Drugs Forecast Market, 2016-2020

Figure 100: South America Metabolic Disorders Drugs Market, 2016, By Segment

Figure 101: Brazil Metabolic Disorders Drugs Historic Market, 2012-2016

Figure 102: Brazil Metabolic Disorders Drugs Forecast Market, 2016-2020

Figure 103: Brazil Metabolic Disorders Drugs Market, 2016, By Segment

Figure 104: Brazil Metabolic Disorders Drugs Percentage Of GDP, 2012-2020

Figure 105: Brazil Per Capita Average Metabolic Disorders Drugs Expenditure, 2012-2020

Figure 106: Middle East Metabolic Disorders Drugs Historic Market, 2012-2016

Figure 107: Middle East Metabolic Disorders Drugs Forecast Market, 2016-2020

Figure 108: Middle East Metabolic Disorders Drugs Market, 2016, By Segment

Figure 109: Africa Metabolic Disorders Drugs Historic Market, 2012-2016

Figure 110: Africa Metabolic Disorders Drugs Forecast Market, 2016-2020

Figure 111: Africa Metabolic Disorders Drugs Market, 2016, By Segment

Figure 112: Novo Nordisk Financial Performance

Figure 113: Sanofi Financial Performance

Figure 114: Merck & Co. Financial Performance

Figure 115: Eli Lilly Financial Performance

Figure 116: Astrazeneca PLC Financial Performance

Figure 117: Pharmaceutical Drugs Market Historic Growth

Figure 118: Pharmaceutical Drugs Market Forecast Growth

Figure 119: Global Pharmaceutical Drugs Market, 2016, By Region

Figure 120: Global Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Region

Figure 121: Pharmaceutical Drugs Market, 2016, By Country

Figure 122: Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Country

Figure 123: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment

Figure 124: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment

Figure 125: Pharmaceutical Drugs Market Size, Percentage Of GDP, Global

Figure 126: Per Capita Average Pharmaceutical Drugs Expenditure, Global

Figure 127: Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries

Figure 128: Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country

Figure 129: Per Capita Average Pharmaceutical Drugs Expenditure, By Country

Figure 130: Pharmaceuticals Industry Financial Margins

  • Single User License (for access by one person)
  • Site License (for access of one office location of a company)
  • Corporate License (allow access by all staff of the company)
To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Anti-Diabetics, Anti-Thyroid Drugs, Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)


Companies

Novo Nordisk, Sanofi, Merck & Co., Eli Lilly, and AstraZeneca PLC